Repertoire

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

Retrieved on: 
Monday, April 29, 2024
Doctor of Philosophy, Flagship Pioneering, BMY, Epitope, Research, Vaccine, Repertoire, Disease, Autoimmune disease, Patient, Immunology, BMS, Immune system, Bristol Myers Squibb, TCR, Biotechnology, Pharmaceutical industry

CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.

Key Points: 
  • CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases.
  • The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.
  • "We are excited to collaborate with Bristol Myers Squibb to combine their leadership in immunology with our unique ability to discover key disease-associated epitopes in patients with autoimmune diseases.
  • This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease."

Universal Music Group Acquires Chabaka Music, UAE-Based Digitally-Focused Music Marketing and Distribution Agency

Retrieved on: 
Wednesday, August 30, 2023
A&R, Music, Partnership, Marketing, Culture, Artists and repertoire, Repertoire, Universal Music Group, Entrepreneurship, Acquisition, Publishing, Virgin Records, Collection, Artist, UMG, Knowledge, Growth, Virginity, Film industry

LONDON and DUBAI, United Arab Emirates, Aug. 30, 2023 /PRNewswire/ -- Universal Music Group (UMG), the world's leader in music-based entertainment, today announced that it has entered into an agreement to acquire UAE-based music company, Chabaka, part of the CHBK Group.

Key Points: 
  • Chabaka provides digital distribution, marketing, publishing, and label and artist services in the Middle East and North Africa (MENA) region.
  • With offices across the entire MENA region, Chabaka has to date signed agreements with more than 150 independent artists and local labels across the region.
  • The acquisition of Chabaka complements UMG's current service offering and footprint in the fast-growing and dynamic MENA market, which saw growth in recorded music revenues of 23.8% in 2022.
  • Following the acquisition, Chabaka will become part of UMG's Virgin Music Group, working closely with the local Virgin and UMG teams in MENA.

Universal Music Group Acquires Chabaka Music, UAE-Based Digitally-Focused Music Marketing and Distribution Agency

Retrieved on: 
Wednesday, August 30, 2023
A&R, Music, Partnership, Marketing, Culture, Artists and repertoire, Repertoire, Universal Music Group, Entrepreneurship, Acquisition, Publishing, Virgin Records, Collection, Artist, UMG, Knowledge, Growth, Virginity, Film industry

LONDON and DUBAI, United Arab Emirates, Aug. 30, 2023 /PRNewswire/ -- Universal Music Group (UMG), the world's leader in music-based entertainment, today announced that it has entered into an agreement to acquire UAE-based music company, Chabaka, part of the CHBK Group.

Key Points: 
  • Chabaka provides digital distribution, marketing, publishing, and label and artist services in the Middle East and North Africa (MENA) region.
  • With offices across the entire MENA region, Chabaka has to date signed agreements with more than 150 independent artists and local labels across the region.
  • The acquisition of Chabaka complements UMG's current service offering and footprint in the fast-growing and dynamic MENA market, which saw growth in recorded music revenues of 23.8% in 2022.
  • Following the acquisition, Chabaka will become part of UMG's Virgin Music Group, working closely with the local Virgin and UMG teams in MENA.

Repertoire® Immune Medicines Presents New Data From Its DECODE™ Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Other Health, Research, Science, Pharmaceutical, Biotechnology, Repertoire, Flagship Pioneering, Head, Epitope, Prevalence, Human papillomavirus infection, Annual general meeting, EST, Immunotherapy, Interleukin, Research, Cancer, Center, Technology, Development, Population, HPV, CD8, Dana–Farber Cancer Institute, Society for Immunotherapy of Cancer, Haplotype, B cell, Infection, SITC, E7, HLA, Neoplasm, Research and development, E5, OPSCC, Patient, Autoimmune disease, TCR, Society, Degenerative disease, Antigen, Vaccine, E6, Poster

Importantly, we now have data that point to antigens active in driving these malignancies, which we can use to develop novel targeted medicines.

Key Points: 
  • Importantly, we now have data that point to antigens active in driving these malignancies, which we can use to develop novel targeted medicines.
  • DECODE is being used to assess the immunogenicity profile of HPV 16 and HPV 33-positive tumors in oropharyngeal squamous cell carcinoma (OPSCC).
  • Using the DECODE platform, we have a window into the mechanisms involved in the immune surveillance of cancer, which offers us the ability to develop highly selective immune-based medicines, said Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines.
  • Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates.

Torben Straight Nissen Joins Repertoire® Immune Medicines as Chief Executive Officer

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Rubius, B cell, Repertoire, Leadership, Flagship Pioneering, Degenerative disease, Publication, HLA, Maxygen, Epitope, Therapy, Pfizer, HPV, CEO, Infection, Autoimmune disease, Cole, Cancer, Technology, Antigen, Patient, Vaccine

Repertoire Immune Medicines announced today that Torben Straight Nissen has been appointed as interim Chief Executive Officer, succeeding John Cox, who will continue with the company in an advisory role.

Key Points: 
  • Repertoire Immune Medicines announced today that Torben Straight Nissen has been appointed as interim Chief Executive Officer, succeeding John Cox, who will continue with the company in an advisory role.
  • Repertoire has applied its proprietary DECODE platform to develop an unprecedented and unique understanding of the immune synapse.
  • The mission of Repertoire is to discover the immune codes that drive cellular immunity and to use those codes to create new immune medicines, said Cox.
  • I look forward to seeing Repertoire continue its mission to create a new class of immune medicines under Torbens leadership.

New Data From Repertoire® Immune Medicines Demonstrate Effectiveness of Its DECODE™ Platform to Characterize and Identify New Immunotherapeutic Targets in HPV Positive Cancer

Retrieved on: 
Wednesday, October 5, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, TCR, LinkedIn, HLA, Autoimmune disease, SITC, APC, Epitope, Research, Twitter, Annual general meeting, Immunotherapy, Cancer, B cell, Technology, Infection, Society, Toxicity, Repertoire, HPV, Antigen, Society for Immunotherapy of Cancer, Degenerative disease, Vaccine

Repertoire Immune Medicines will present data from its ongoing research to characterize the cellular response and identify novel therapeutic targets with the companys DECODE platform in human papillomavirus (HPV) 16 and HPV 33 positive tumors.

Key Points: 
  • Repertoire Immune Medicines will present data from its ongoing research to characterize the cellular response and identify novel therapeutic targets with the companys DECODE platform in human papillomavirus (HPV) 16 and HPV 33 positive tumors.
  • DECODE is being used to assess the immunogenic profile of HPV 16 and HPV 33 positive tumors in oropharyngeal squamous cell carcinoma.
  • The DECODE platform is a powerful discovery engine that characterizes essential elements of the immune synapse.
  • Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates.

Repertoire® Immune Medicines Enters New Research Collaboration to Discover the T Cell Response to Therapy in HPV-Associated Cancers

Retrieved on: 
Thursday, July 14, 2022
Oncology, Health, Other Health, Research, Science, Biotechnology, Technology, Memorial Sloan Kettering Cancer Center, Map, Development, Master of Science, LinkedIn, Patient, MSK, Infection, Research, Â, Autoimmune disease, Cell, Epitope, Repertoire, HLA, Cancer, Therapy, Research and development, B cell, Neoplasm, Antigen, TCR, Twitter, Immune system, Degenerative disease, Vaccine, MD

Understanding the adaptive immune systems response to cancer allows us to see how it initially responds to diseased cells.

Key Points: 
  • Understanding the adaptive immune systems response to cancer allows us to see how it initially responds to diseased cells.
  • When cancer spreads, it is a signal that the immune system can no longer recognize or defend against the cancer, said Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines.
  • The goal of this research collaboration between Memorial Sloan Kettering and Repertoire is to identify the TCR-antigen pairs that are activated when the immune system is successful in fighting HPV+ cancers.
  • Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates.

Repertoire® Immune Medicines Identifies Novel Immune Targets Involved in Pathogenesis of Type 1 Diabetes

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, Health, Clinical Trials, Cancer, Infection, B cell, Epitope, Technology, HLA, Research, Autoimmune disease, LinkedIn, Antigen, Repertoire, Degenerative disease, Disease, DNA, Immune system, Research and development, Development, Twitter, Patient, Vaccine, T1D

Our DECODE platform allows us to identify the specificity of T cells that cause the dysregulated immune response underlying type 1 diabetes.

Key Points: 
  • Our DECODE platform allows us to identify the specificity of T cells that cause the dysregulated immune response underlying type 1 diabetes.
  • Repertoire is investigating optimal modalities to deliver immune medicines that target the identified epitopes and potentially treat T1D.
  • Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates.
  • Repertoire Immune Medicines is a clinical-stage biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function.

Rubric Capital Management Sends Letter to Radius Health Board of Directors

Retrieved on: 
Thursday, June 16, 2022
Professional Services, Health, Finance, General Health, Banking, Pharmaceutical, Time, Security (finance), NDA, Behavior, Economics, Sex hormone, CEO, Company, U.S. Securities and Exchange Commission, Independence, Repertoire, ATOM, Growth, Letter, NOLS, Novin, SC, Intention, Nature, NPV, Board, Employment, Language, Insurance, Music, Management, Radius, Abaloparatide, EBITDA

I am writing you on behalf of Rubric Capital Management LP (together, Rubric, we, or our), whose managed funds and accounts collectively own approximately 14.62% of the common stock of Radius Health, Inc. (the Company or Radius).

Key Points: 
  • I am writing you on behalf of Rubric Capital Management LP (together, Rubric, we, or our), whose managed funds and accounts collectively own approximately 14.62% of the common stock of Radius Health, Inc. (the Company or Radius).
  • Assuming a conservative 6.0x current year EBITDA, the Tymlos franchise alone is worth $600 million, or about the total enterprise value of Radius today.
  • We are not sure how the Radius Board benefits by adding a squad of Mr. Martin's allies pulled from those companies.
  • In our view, this is the behavior of a Board and management team that are not aligned with their shareholders and is unacceptable at any company.

SUSAN JAFFE NAMED ARTISTIC DIRECTOR OF AMERICAN BALLET THEATRE

Retrieved on: 
Monday, May 9, 2022
Board, UNCSA, COVID-19, Pittsburgh Ballet Theatre, American Ballet Theatre, La Scala Theatre Ballet, University, ABT, The New York Times, Royal Danish Ballet, Company, Mariinsky Ballet, Time, Repertoire, Curriculum, American Ballet, Faculty, Vienna State Ballet, Art, Principal dancer, Trustee, Leadership, History, Multimedia, Artistic director, PBT, English National Ballet, University of North Carolina School of the Arts, Stuttgart Ballet, The Royal Ballet, Stuttgart, Museum, Royal Swedish Ballet, Sleeping Beauty, City, Entertainment

NEW YORK, May 9, 2022 /PRNewswire/ -- Former American Ballet Theatre Principal Dancer Susan Jaffe has been named the Company's next Artistic Director.

Key Points: 
  • NEW YORK, May 9, 2022 /PRNewswire/ -- Former American Ballet Theatre Principal Dancer Susan Jaffe has been named the Company's next Artistic Director.
  • "What a profound honor it is for me to come back home to lead the artistic helm of American Ballet Theatre," said Jaffe.
  • She performed on the international stage with the Royal Ballet, the Kirov Ballet, the Stuttgart Ballet, La Scala Ballet, Vienna State Opera Ballet, Royal Danish Ballet, Royal Swedish Ballet, and the English National Ballet.
  • A choreographer herself, Jaffe has created works for American Ballet Theatre, ABT Studio Company, Grand Rapid Ballet's Move Media, Company C Contemporary Ballet, Configurations Dance Theatre, and Pittsburgh Ballet Theatre, among others.